CNS Disorders  >>  azeliragon (TTP488)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
azeliragon (TTP488) / Cantex Pharma
NCT00141661: A Safety and Tolerability Evaluation of Two 10-Week Dose Regimens of Orally-Administered PF-04494700 in Alzheimer's Patients

Completed
2a
67
US
PF-04494700 - Low Dose Arm, PF-04494700 - High Dose Arm, Placebo Comparator
Pfizer, Trans Tech Pharmaceuticals
Alzheimer Disease
06/06
06/06
NCT00566397: A Phase 2 Study Evaluating The Efficacy And Safety Of PF 04494700 In Mild To Moderate Alzheimer's Disease

Completed
2
402
US
PF-04494700, Placebo
Pfizer, Alzheimer's Disease Cooperative Study (ADCS)
Alzheimer's Disease
12/10
12/10
NCT03980730: Study of Azeliragon in Patients With Mild Alzheimer's Disease and Impaired Glucose Tolerance

Hourglass Jul 2021 - Dec 2021 : Initiation of P3 part of P2/3 Elevage trial for Alzheimers disease
Hourglass Jan 2021 - Jun 2021 : Top-line results in mild Alzheimer's disease patients with type 2 diabetes
Terminated
2
43
Canada, US
Azeliragon, TTP488, Placebo
vTv Therapeutics
Alzheimer Disease
12/20
01/21

Download Options